CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $318,000 | +34.2% | 4,200 | +98.4% | 0.01% | +33.3% |
| Q3 2021 | $237,000 | -30.7% | 2,117 | +0.1% | 0.01% | -40.0% |
| Q2 2021 | $342,000 | +165.1% | 2,115 | +37.6% | 0.01% | +66.7% |
| Q3 2020 | $129,000 | -64.6% | 1,537 | -68.9% | 0.01% | -70.0% |
| Q2 2020 | $364,000 | +3.7% | 4,950 | -33.5% | 0.02% | +17.6% |
| Q2 2019 | $351,000 | +17.8% | 7,446 | +46.6% | 0.02% | -10.5% |
| Q2 2018 | $298,000 | -41.5% | 5,078 | -54.4% | 0.02% | -48.6% |
| Q1 2018 | $509,000 | -13.6% | 11,131 | -55.7% | 0.04% | -21.3% |
| Q4 2017 | $589,000 | – | 25,106 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |